The 6th TimePie Longevity Forum in Shanghai brought together approximately 2,500 participants from 16 countries across aging biology, biomarker development and clinical geroscience. Discussion centered on building biomarker frameworks robust enough to guide the testing of interventions in humans, rather than on mechanistic discovery alone. The translational bottleneck in geroscience remains measurement: without validated indicators of biological aging, intervention trials lack meaningful endpoints.
Key Points
- 2,500 participants from 16 countries convened in Shanghai, September 2025
- Focus on biomarker frameworks guiding human intervention trials
- Translation from mechanistic aging biology to clinical geroscience emphasized
Longevity Analysis
Intervention science advances only as fast as its measurement tools. Validated markers of biological aging would allow clinicians to distinguish genuine shifts in regenerative capacity, immune competence, metabolic efficiency and cardiovascular resilience from statistical noise, and to determine whether a given protocol is working within a practical time horizon rather than over decades. For practitioners, the value lies in interpreting what the body is already signaling with greater precision, then sustaining an intervention long enough for those signals to register a change.
Original published by Nature Aging, by Kejun Ying.